Skip to main content
SpringerLink
Log in

Per quanto tempo curare il morbo di Basedow con le tionamidi

  • TIROIDE
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9(12):724–734

    Article  CAS  Google Scholar 

  2. Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 97(12):4549–4584

    Article  CAS  Google Scholar 

  3. Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 84(1):115–120

    Article  CAS  Google Scholar 

  4. Brito JP, Schilz S, Singh Ospina N et al. (2016) Antithyroid drugs the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid 26(8):1144–1445

    Article  Google Scholar 

  5. Vitti P, Rago T, Chiovato L et al. (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7(3):369–375

    Article  CAS  Google Scholar 

  6. Rotondi M, Virili C, Pinto S et al. (2020) The clinical phenotype of Graves’ disease occurring as an isolated condition or in association with other autoimmune diseases. J Endocrinol Invest 43(2):157–162

    Article  CAS  Google Scholar 

  7. Masiello E, Veronesi G, Gallo D et al. (2018) Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41:1425–1432

    Article  CAS  Google Scholar 

  8. Struja T, Kaeslin M, Boesiger F et al. (2017) External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol 176(4):413–419

    Article  CAS  Google Scholar 

  9. Park S, Song E, Oh H-S et al. (2019) When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued? Endocrine 65(2):348–356

    Article  CAS  Google Scholar 

  10. Bandai S, Okamura K, Fujikawa M et al. (2019) The long-term follow-up of patients with thionamide-treated Graves’ hyperthyroidism. Endocr J 66(6):535–545

    Article  CAS  Google Scholar 

  11. Cooper DS (2019) Long-term antithyroid drug treatment of patients with Graves disease. Clin Thyroidol 31:230–233

    Article  Google Scholar 

  12. Azizi F, Malboosaf R (2019) Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest 42(11):1273–1283

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituti Clinici Scientifici Maugeri, Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, Pavia, Italia

    Luca Chiovato

  2. Dipartimento di Medicina e Chirurgia, Università dell’Insubria, Varese, Italia

    Luigi Bartalena

  3. Dipartimento di Medicina Clinica Sperimentale, Università di Pisa, Pisa, Italia

    Paolo Vitti

  4. Accademia Peloritana dei Pericolanti presso l’Università di Messina, Messina, Italia

    Francesco Trimarchi

Authors
  1. Luca Chiovato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luigi Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Vitti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Trimarchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Trimarchi.

Ethics declarations

Conflitto di interesse

Gli autori Luca Chiovato, Luigi Bartalena, Paolo Vitti e Francesco Trimarchi dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chiovato, L., Bartalena, L., Vitti, P. et al. Per quanto tempo curare il morbo di Basedow con le tionamidi. L'Endocrinologo 21 (Suppl 1), 67–69 (2020). https://doi.org/10.1007/s40619-020-00721-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-020-00721-3

Search

Navigation